News

As part of the deal, Adimab will use its proprietary platform to produce therapeutic antibodies and bispecifics molecules against multiple targets, which will be developed and commercialized by

Velcade was approved for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone to treat MCL patients who are unsuitable for blood stem-cell transplantation. Currently, Velcade is indicated

The facility, which is expected to come online in early 2016, will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s

In addition, the Russian Patent Office issued a first notification to grant patent coverage of the Company’s lead therapeutic candidate, NNI-351, for pharmaceutical composition and a method of

Going forward, the "ChromaDex Quality Verified Seal" will be added to the entire line of BPI Sports’ protein powders, assuring that each product has been third-party tested and

The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. Elsiglutide is a novel GLP-2

Entrectinib is a new, orally available, selective tyrosine kinase inhibitor and is designed as a targeted therapeutic candidate to treat patients with cancers that harbor activating alterations to

As part of the deal, Hapten received a one-time upfront cash payment of $100,000 and 200,000 shares of RXi common stock. Hapten will also be eligible to receive

Nocdurna (desmopressin orally disintegrating tablets) is an antidiuretic that contains desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin. The drug works by stimulating vasopressin receptors